We don't know. It may be a normal update, with management
We don't know. It may be a normal update, with management wanting to have a chance to address shareholders' questions in a less stressful time. Remember they had to do taxes, the 10-Q, and who knows what to get ready for these conferences this summer. By early June all that stuff should be done -- no one starts writing a presentation the week before they go to the conference. Well, at least they shouldn't try to do that.....
Or there may be some kind of clinical trial update. But the fact that they want questions in advance says to me that this is just an ordinary, good shareholder-relations thing.
Please remember that bashers want to set up huge expectations, then when there isn't some huge news, they use that as an excuse to pound the stock. So don't fall into their trap -- let's just wait and see, and not build up huge expectations.
By the way I applaud their decision to require questions in advance. Just think of the level of discourse we've seen at lieHUB. Imagine having some of those people pipe up with BS -- there's no good way to handle disruptive, dishonest "questioners" that does anything but give the company a black eye.
3
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Sales Focus Inc.: Leading the Way in Healthcare Outsourcing Sales Focus Inc. (SFI) proudly announces its recognition as the Top Healthcare and Medical Sales Outsourcing Service for 2025. This prestigious accolade showcases the company's vital role in revolutionizing the healthcare sector with its innovative full-lifecycle sales execution model and robust industry...
Continue Reading
Exploring the Autonomous Data Platform Market Growth The world of data management is rapidly evolving, with the Autonomous Data Platform Market projected to reach an impressive USD 14.96 billion by 2032. This explosive growth expands at a significant CAGR of 27.89% from its current valuation, representing a fundamental shift in how organizations interact with their data....
Continue Reading
Insider Purchase by William Abbey at Enpro In the latest SEC filing, the market received noteworthy news about Enpro. William Abbey, who serves as a Director at Enpro (NYSE:NPO), demonstrated significant confidence in the company by purchasing 567 shares for a total of $139,997. What This Purchase Indicates This insider transaction suggests a strong belief in Enpro's...
Continue Reading
BNB Donation Achieves Remarkable Growth Recently, an incredible story surfaced about the untouched donation made in BNB (CRYPTO: BNB) for cancer patients. This donation, originally valued at $200,000, has soared to an astonishing $39 million thanks to the surging market value of cryptocurrencies, particularly BNB. Impact of Cryptocurrency Fluctuation on Charity Funds...
Continue Reading
Bio X Cell Unveils a Fresh Brand Identity Bio X Cell, recognized as the global leader in functional antibodies tailored for in vivo and emerging preclinical models, has introduced a modernized brand identity. This change is a testament to nearly three decades of excellence in the field, seamlessly merging scientific innovation with expanding global capabilities in...
Continue Reading